Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX
NASDAQNVAX
FormDescriptionDateFormat
CORRESPCorrespondence from the Filer to the SECDec 23, 2010Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
UPLOADCorrespondence from the SEC to the FilerDec 21, 2010Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.
CT ORDERConfidential treatment orderAug 30, 2010Open Confidential treatment order in HTML.Open Confidential treatment order in DOC file.Open Confidential treatment order in PDF file.Open Confidential treatment order in XLS file.
EFFECTNotice from the SEC of registration effectivenessApr 28, 2010Open Notice from the SEC of registration effectiveness in HTML.Open Notice from the SEC of registration effectiveness in DOC file.Open Notice from the SEC of registration effectiveness in PDF file.Open Notice from the SEC of registration effectiveness in XLS file.
CORRESPCorrespondence from the Filer to the SECApr 26, 2010Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
CT ORDERConfidential treatment orderApr 26, 2010Open Confidential treatment order in HTML.Open Confidential treatment order in DOC file.Open Confidential treatment order in PDF file.Open Confidential treatment order in XLS file.
UPLOADCorrespondence from the SEC to the FilerMar 23, 2010Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.
SC 13G/AAmendment to a previously filed SC 13GFeb 12, 2010Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
SC 13G/AAmendment to a previously filed SC 13GFeb 9, 2010Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 3, 2010Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
SC 13G/AAmendment to a previously filed SC 13GFeb 2, 2010Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.